Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

MERS Vaccine Candidate Produces Immune Response in Lab Test

(U.S. Army Corps of Engineers)

30 April 2014. Researchers at the biotechnology company Novavax Inc. in Gaithersburg, Maryland and University of Maryland medical school in Baltimore found new vaccines made from engineered protein nanoparticles generated in lab mice an immune response to the Middle East Respiratory Syndrome (MERS) and severe acute respiratory syndrome . . . → Read More: MERS Vaccine Candidate Produces Immune Response in Lab Test

Alzheimer’s Brain Stimulation Implants Completed for Trial

Andres Lozano (University of Toronto)

30 April 2014. A clinical trial testing the safety and potential benefit of deep brain stimulation to treat Alzheimer’s disease completed implanting stimulation devices in enrolled patients in the U.S. and Canada. Functional Neuromodulation Ltd, in Toronto and Charlottesville, Virginia says it expects to report the first results . . . → Read More: Alzheimer’s Brain Stimulation Implants Completed for Trial

Tablet App Provides Feedback, Improves Drug Adherence

Android tablet app dashboard display. Medication feedback is provided in the top section of the screen. (dwellsense.com)

29 April 2014. Computer scientists at Carnegie Mellon University in Pittsburgh designed and tested a tablet app, connected to electronic sensors on a pillbox, that provides feedback to older adults and helps them stick to their medication . . . → Read More: Tablet App Provides Feedback, Improves Drug Adherence

Mayo Clinic Offering Gene Test to Target Chemotherapy

(National Institutes of Health)

29 April 2014. Mayo Clinic in Rochester, Minnesota now offers cancer patients with solid tumors a test that enables physicians to tailor chemotherapy drugs to the patient’s specific genetic background. The test known as Solid Tumor Targeted Cancer Panel or CANCP is available to patients at the Mayo Clinic . . . → Read More: Mayo Clinic Offering Gene Test to Target Chemotherapy

FDA Approves Intermediate ALS Stem Cell Clinical Trial

(National Institute on Aging, NIH)

28 April 2014. BrainStorm Cell Therapeutics, in New York and Israel, says the U.S. Food and Drug Administration approved its beginning an intermediate stage clinical trial of a stem cell-based therapy for amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease. The trial will test for . . . → Read More: FDA Approves Intermediate ALS Stem Cell Clinical Trial

Diagnostics Firm Licenses Severe Food Allergy Gene Research

(James. J. Caras, National Science Foundation)

28 April 2014. Diagnovus LLC, a molecular diagnostics developer in Nashville, is licensing research on food allergies to detect a severe type of allergic condition based on a patient’s genetics. Financial terms of the deal with Cincinnati Children’s Hospital Medical Center that conducted the research were not . . . → Read More: Diagnostics Firm Licenses Severe Food Allergy Gene Research

Cancer Immunotherapy Start-Up Completes $176M Funding Round

Acute myeloid leukemia cells (Cancer Genome Atlas)

25 April 2014. Juno Therapeutics, a biotechnology start-up company in Seattle, completed its first round of venture financing, raising $176 million from private investors and not-for-profit research institutes. The company started in December 2013 with a stake of $120 million, but announced in January 2014 it . . . → Read More: Cancer Immunotherapy Start-Up Completes $176M Funding Round

Simple, Low-Cost Method Adds Microscope Lens to Smartphone

Steve Lee holds a slide with four droplet lenses. (Stuart Hay, Australian National University)

25 April 2014. Engineers at Australian National University in Canberra devised an inexpensive process to make an add-on lens that turns a smartphone into a high-powered microscope. The team led by ANU’s Woei Ming (Steve) Lee published its technique . . . → Read More: Simple, Low-Cost Method Adds Microscope Lens to Smartphone

Genome Editing Start-Up Secures $25 Million in First Round

Emmanuelle Charpentier (Helmholtz Centre for Infection Research)

24 April 2014. Biopharmaceutical start-up company CRISPR Therapeutics in Basel, Switzerland raised $25 million in its first funding round. The company develops engineered gene therapies with a technology developed by one of its scientific founders, and is backed in this round by Versant Ventures, a venture capital company . . . → Read More: Genome Editing Start-Up Secures $25 Million in First Round

Electro-Gene Therapy with Cochlear Implant Boosts Hearing

Inside of the cochlea after DNA delivery. The green spots show the location of cells that are expressing the therapeutic gene, which is close to where the cochlear implant electrodes were positioned. (J. Pinyon and G. Housley, UNSW)

24 April 2014. Researchers at University of New South Wales in Sydney, Australia delivered genetic . . . → Read More: Electro-Gene Therapy with Cochlear Implant Boosts Hearing